CHI3L1 and Cognitive impairment: Our study provides compelling evidence that targeting CHI3L1 with a monoclonal antibody (H1) mitigates key pathological features of AD in Tg2576 mouse, including neuroinflammation, amyloid deposition, and cognitive impairment.